Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Non-Controlling Interests (Details)

Non-Controlling Interests (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Noncontrolling Interest [Line Items]
NCI equity share	$ 120,298		$ 120,298		$ 108,017
Net loss attributable to non-controlling interests	(14,417)	$ (12,208)	(41,264)	$ (44,237)	(61,700)
Non-controlling interests in consolidated entities	79,034		79,034		46,317
Aevitas [Member]
Noncontrolling Interest [Line Items]
NCI equity share	(2,297)		(2,297)		(1,249)
Net loss attributable to non-controlling interests			(680)		(694)
Non-controlling interests in consolidated entities	$ (2,977)		$ (2,977)		$ (1,943)
Non-controlling ownership	39.00%		39.00%		35.80%
Avenue [Member]
Noncontrolling Interest [Line Items]
NCI equity share	$ 5,709		$ 5,709		$ 24,269
Net loss attributable to non-controlling interests			(3,206)		(19,011)
Non-controlling interests in consolidated entities	$ 2,503		$ 2,503		$ 5,258
Non-controlling ownership	77.40%		77.40%		77.30%
Baergic[Member]
Noncontrolling Interest [Line Items]
NCI equity share	$ (1,605)		$ (1,605)		$ 23
Net loss attributable to non-controlling interests			(68)		(1,162)
Non-controlling interests in consolidated entities	$ (1,673)		$ (1,673)		$ (1,139)
Non-controlling ownership	40.00%		40.00%		33.00%
Cellvation [Member]
Noncontrolling Interest [Line Items]
NCI equity share	$ (1,072)		$ (1,072)		$ (732)
Net loss attributable to non-controlling interests			(145)		(158)
Non-controlling interests in consolidated entities	$ (1,217)		$ (1,217)		$ (890)
Non-controlling ownership	22.60%		22.60%		20.60%
Checkpoint [Member]
Noncontrolling Interest [Line Items]
NCI equity share	$ 37,963		$ 37,963		$ 29,389
Net loss attributable to non-controlling interests			(9,000)		(14,687)
Non-controlling interests in consolidated entities	$ 28,963		$ 28,963		$ 14,702
Non-controlling ownership	80.00%		80.00%		78.00%
Coronado SO [Member]
Noncontrolling Interest [Line Items]
NCI equity share	$ (290)		$ (290)		$ (290)
Net loss attributable to non-controlling interests			0		0
Non-controlling interests in consolidated entities	$ (290)		$ (290)		$ (290)
Non-controlling ownership	13.00%		13.00%		13.00%
Cyprium [Member]
Noncontrolling Interest [Line Items]
NCI equity share	$ 784		$ 784		$ (320)
Net loss attributable to non-controlling interests			(843)		(99)
Non-controlling interests in consolidated entities	$ (59)		$ (59)		$ (419)
Non-controlling ownership	28.40%		28.40%		10.60%
Helocyte [Member]
Noncontrolling Interest [Line Items]
NCI equity share	$ (4,890)		$ (4,890)		$ (4,322)
Net loss attributable to non-controlling interests			(236)		(402)
Non-controlling interests in consolidated entities	$ (5,126)		$ (5,126)		$ (4,724)
Non-controlling ownership	18.80%		18.80%		19.30%
JMC [Member]
Noncontrolling Interest [Line Items]
NCI equity share	$ 123		$ 123		$ (211)
Net loss attributable to non-controlling interests			257		325
Non-controlling interests in consolidated entities	$ 380		$ 380		$ 114
Non-controlling ownership	6.90%		6.90%		6.90%
Mustang [Member]
Noncontrolling Interest [Line Items]
NCI equity share	$ 86,572		$ 86,572		$ 62,025
Net loss attributable to non-controlling interests			(27,035)		(25,727)
Non-controlling interests in consolidated entities	$ 59,537		$ 59,537		$ 36,298
Non-controlling ownership	77.90%		77.90%		70.30%
Oncogenuity [Member]
Noncontrolling Interest [Line Items]
NCI equity share	$ (47)		$ (47)
Net loss attributable to non-controlling interests			(268)
Non-controlling interests in consolidated entities	$ (315)		$ (315)
Non-controlling ownership	25.30%		25.30%
Tamid [Member]
Noncontrolling Interest [Line Items]
NCI equity share	$ (652)		$ (652)		$ (565)
Net loss attributable to non-controlling interests			(40)		(85)
Non-controlling interests in consolidated entities	$ (692)		$ (692)		$ (650)
Non-controlling ownership	22.80%		22.80%		22.80%